Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Open for Business: Early Phase Clinical Drug Development during the COVID-19 Pandemic

The global COVID-19 pandemic has altered the mechanics of nearly every industry. For early phase clinical trials, adapting to this crisis has led to augmented risk mitigation procedures and greater use of innovative technology. Since continuity of your drug program is important to you, the patients in need of these therapies, it is important to us.

We have taken a proactive approach to conducting business, now when research is needed more than ever. Our strengths lie in being flexible and nimble, which is a benefit during times of uncertainty.

Our ‘New Normal’ is built on three key pillars; Safety, Resources and Communication.

Safety First

The health and safety of our participant and staff is of the utmost importance. We have incorporated several measures to screen, clean and isolate for COVID-19 virus during trial operations. We are following all CDC, FDA and MHRA guidelines as well as local regulations   for clinical operations during the COVID-19 pandemic.

Testing, Testing, Testing! Celerion Bioanalytical Services has focused capabilities on COVID-19 screening by PCR, viral load quantification, antigen detection, antibody titer measurement, cell-mediated immunity assessments as well as cytokine and chemokine inflammation biomarker assays.


We Lead Quality


We have the essential resources in place to safely and effectively execute your clinical trial.

Communication is Key

With conditions rapidly changing, effective communication among all stakeholders is critical.

During this dynamic situation, the steps we have put in place for the safety of participants and staff, securing supply chain and innovative technology are designed with one objective in mind, to help our biotech and pharma partners get their products to market faster.

Contact the Author